Anupam Rasayan delivered robust financial results for the first quarter of FY27, with consolidated net profit rising 6% year-on-year to ₹512 crore from ₹485.8 crore in the corresponding quarter last year. According to reports from Business Standard, the company's revenue increased 35% YoY to ₹6,550 crore from ₹4,858 crore in the year-ago period. EBITDA improved 35% to ₹1,749 crore from ₹1,243 crore, demonstrating strong operational performance across key metrics.
While the company achieved strong revenue and profit growth, EBITDA margin remained flat at 26% in the June 2026 quarter, as reported by Business Standard. This represents a slight moderation in profitability margins despite the significant revenue expansion. The margin compression indicates that while the company scaled operations effectively, the cost structure may have increased proportionally to support the higher revenue base. Profit before tax stood at ₹697 crore, up 11% from ₹629 crore in Q1 FY26, showing continued improvement in pre-tax performance.
The company's cost breakdown for Q1 FY27 shows cost of materials consumed at ₹2,847 crore (up 17% YoY), employee expenses at ₹649 crore (up 220% YoY), and other expenses at ₹1,430 crore (up 47% YoY), as reported by Business Standard. The significant increase in employee expenses reflects the company's expansion and hiring activities to support its growing operations and strategic initiatives.
Anand Desai, Managing Director, highlighted significant strategic achievements during the quarter, stating that the company became the first in the world to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry, a significant advancement that strengthens their capabilities in complex fluorination. The company also signed a Letter of Intent with BASQUEVOLT, S.A. for potential long-term supply of a specialty chemical product, representing a revenue opportunity of approximately US$300 million spread over a period of ten years. Additionally, the proposed acquisition of Bliss GVS Pharma continues to progress as planned, following the signing of the definitive agreement.
Anupam Rasayan shares rose 0.34% to currently trade at ₹1,213 on the BSE following the results announcement, as reported by Business Standard. The positive market reaction reflects investor confidence in the company's strong quarterly performance and strategic initiatives, including the technological milestone and significant contract wins. The stock performance indicates mixed investor sentiment despite the strong quarterly results, with the company maintaining its position as one of India's leading specialty chemicals manufacturers.
